Pyrazinamide-induced acute gouty arthritis: a case report


  • Airenakho Emorinken Department of Internal Medicine, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
  • Asuwemhe J. Ugheoke Department of Internal Medicine, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria



Acute gout, Hyperuricemia, Pulmonary tuberculosis, Pyrazinamide


Gout is a common inflammatory and metabolic disease caused by the deposition of monosodium urate crystals in articular and non-articular tissues. Drugs used to treat tuberculosis, such as pyrazinamide and ethambutol, have been linked to hyperuricaemia. However, acute gout is uncommon. We report a case of a 28-year-old female who developed acute gouty arthritis of the left knee joint as a result of taking pyrazinamide as part of a tuberculosis therapy regimen. Although pyrazinamide-induced hyperuricemia is frequently regarded as asymptomatic, the clinician should be aware of the likelihood of acute gouty arthritis, which can result in significant morbidity and an impaired quality of life.


Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology. 2017;56(5):679-88.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136-41.

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960-6.

Adelowo O, Umar A, Oguntona S. Gouty arthritis in Nigerians: clinical and laboratory correlates. Afr J Rheumatol. 2014;2(1):23-8.

Campion EW, Glynn RJ, Labry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421-6.

Abhishek A, Roddy E, Doherty M. Gout - a guide for the general and acute physicians. Clin Med. 2017;17(1):54-9.

Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective - A review. J Adv Res. 2017;8(5):495-511.

Paulus HE, Coutts A, Calabro JJ, Klinenberg JR. Clinical significance of hyperuricemia in routinely screened hospitalized men. JAMA. 1970;211(2):277-81.

Inayat N, Shah RH, Lakhair MA, Sahito R. Hyperuricemia and arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis. Pak J Chest Med. 2016;22(4):154-8.

Qureshi W, Hassan G, Kadri SM, Khan GQ, Samuel B, Arshad A. Hyperuricemia and arthralgias during pyrazinamide therapy in patients with pulmonary tuberculosis. Lab Med. 2007;38(8):495-7.

Inoue T, Ikeda N, Kurasawa T, Sato A, Nakatani K, Ikeda T, et al. Hyperuricemia and arthralgia during pyrazinamide treatment. Nihon Kokyuki Gakkai Zasshi. 1999;37(2):115-8.

Shapiro M, Hyde L. Hyperuricemia due to pyrazinamide. Am J Med. 1957;23(4):596-9.

Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. P T. 2014;39(10):695-715.

Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-52.

Khanna BK, Gupta VP, Singh MP. Ethambutol-induced hyperuricaemia. Tubercle. 1984;65(3):195-9.

Postlethwaite AE, Bartel AG, Kelley WN. Hyperuricemia due to ethambutol. N Engl J Med. 1972;286(14):761-2.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789-98.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-55.




How to Cite

Emorinken, A., & Ugheoke, A. J. (2022). Pyrazinamide-induced acute gouty arthritis: a case report. International Journal of Research in Medical Sciences, 10(2), 526–529.



Case Reports